Dr. Lal PathLabs share price
You have to be logged in to add this to Watchlist.- ₹1,432.55(3.76%)April 15, 2026 15:29:42 PM IST
- NSE
- BSE
- Vol : 544.10 K (NSE + BSE)Last 20 day avg : 351.58 K
Dr. Lal PathLabs is trading 3.76% upper at Rs 1,432.55 as compared to its last closing price. Dr. Lal PathLabs has been trading in the price range of 1,473.35 & 1,383.45. Dr. Lal PathLabs has given -6.93% in this year & 2.03% in the last 5 days. Dr. Lal PathLabs has TTM P/E ratio 46.74 as compared to the sector P/E of 27.63.There are 23 analysts who have initiated coverage on Dr. Lal PathLabs. There are 7 analysts who have given it a strong buy rating & 11 analysts have given it a buy rating. 3 analysts have given the stock a sell rating.The company posted a net profit of 90.50 Crores in its last quarter.Listed peers of Dr. Lal PathLabs include Global Health (2.41%), Narayana Hrudayalaya (1.59%), Fortis Healthcare (2.76%).The Mutual Fund holding in Dr. Lal PathLabs was at 16.84% in 31 Dec 2025. The MF holding has increased from the last quarter. The FII holding in Dr. Lal PathLabs was at 20.29% in 31 Dec 2025. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on Apr 15, 2026, 11:15 PM UTC
- BetaMedium volatility0.93Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.07The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldInline with the industry0.94Annual dividends as a percentage of the stock price.
- PEG RatioIndicates overvaluation3.63The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
|
| ||||
|
| ||||
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Global Health | Neutral | 1,086.55 | 2.41 | 29,231.60 | 61.73 | 9.45 | 0.04 | 18.41 |
| Narayana Hrudayalaya | Neutral | 1,797.25 | 1.59 | 36,814.06 | 47.66 | 10.51 | 0.24 | 59.03 |
| Fortis Healthcare | Neutral | 873.80 | 2.76 | 66,034.25 | 80.04 | 7.64 | 0.11 | 25.92 |
| Max Healthcare Institute | Neutral | 989.95 | 4.07 | 96,462.89 | 93.43 | 11.21 | 0.14 | 29.50 |
| Apollo Hospitals Enterprise | Bullish | 7,628.60 | 1.51 | 1,09,749.62 | 71.09 | 12.56 | 0.26 | 83.18 |
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-04-30 | Audited Results |
| 2026-01-30 | Quarterly Results & Interim Dividend |
| 2025-10-31 | Qtr Results, Int.Dividend & Bonus issue |
| 2025-07-31 | Quarterly Results, Dividend & Others |
| 2025-04-25 | Audited Results & Final Dividend |
- IndustryHealthcare Facilities
- ISININE600L01024
- BSE Code539524
- NSE CodeLALPATHLAB
Dr. Lal PathLabs is trading at 1432.55 as on Wed Apr 15 2026 09:59:42. This is 3.76% upper as compared to its previous closing price of 1380.60.
The market capitalization of Dr. Lal PathLabs is 23954.52 Cr as on Wed Apr 15 2026 09:59:42.
The average broker rating on Dr. Lal PathLabs is Buy. The breakup of analyst rating is given below -
- 7 analysts have given a strong buy rating
- 11 analysts have given a buy rating
- 2 analysts have given a hold rating
- 3 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Dr. Lal PathLabs is 1771.30 whereas the 52 wk low is 1272.00
Dr. Lal PathLabs can be analyzed on the following key metrics -
- TTM P/E: 46.74
- Sector P/E: 27.63
- Dividend Yield: 0.94%
- D/E ratio: -
Dr. Lal PathLabs reported a net profit of 487.14 Cr in 2025.
The Mutual Fund Shareholding was 16.84% at the end of 31 Dec 2025.